Sagent Pharmaceuticals, Inc.
DelistedCIK 1369786fmd_0RRKR0NE8W73FWGFV97QQPD97MManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Jun 30, 2016, 26 periods
| Line item | FY2009 | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 |
|---|---|---|---|---|---|---|---|
| Cost of revenue | 29 | 65 | 134 | 153 | 167 | 203 | 231 |
| Gross profit | 0 | 9 | 19 | 31 | 78 | 86 | 88 |
| Research and development | 12 | 11 | 13 | 17 | 20 | 27 | 29 |
| Selling, general and administrative | 17 | 19 | 25 | 30 | 36 | 43 | 50 |
| Total operating expenses | 31 | 32 | 40 | 47 | 54 | 67 | 85 |
| Operating income | (30) | (23) | (22) | (15) | 31 | 19 | (45) |
| Interest expense | 0 | 1 | 4 | 2 | 1 | 2 | 1 |
| Interest and investment income | – | – | 0 | 0 | 0 | 0 | – |
| Other non-operating income (expense) | – | – | – | 0 | 0 | (1) | (3) |
| Income before taxes | (31) | (24) | (26) | (17) | 30 | 16 | (48) |
| Income tax expense | – | – | – | – | 1 | (21) | (26) |
| Net income from continuing operations | – | – | – | – | 30 | 37 | (22) |
| Net income | (31) | (24) | (26) | (17) | 30 | 37 | (22) |